Aditxt, Inc. (ADTX)
NASDAQ: ADTX · Real-Time Price · USD
1.390
-0.010 (-0.71%)
Jun 18, 2025, 11:52 AM - Market open
Aditxt Employees
Aditxt had 26 employees as of December 31, 2024. The number of employees decreased by 21 or -44.68% compared to the previous year.
Employees
26
Change (1Y)
-21
Growth (1Y)
-44.68%
Revenue / Employee
$2,128
Profits / Employee
-$1,205,157
Market Cap
2.95M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
ADTX News
- 7 days ago - Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting - PRNewsWire
- 9 days ago - Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors - Business Wire
- 13 days ago - Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6 - Business Wire
- 4 weeks ago - Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics - Business Wire
- 6 weeks ago - Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™ - Business Wire
- 2 months ago - Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™ - Business Wire
- 2 months ago - Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025 - Business Wire
- 2 months ago - Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials - Business Wire